This is huge!
Hundreds of clinical trials across the country suggest immunotherapy could be beneficial for more than two dozen kinds of cancer. Former President Jimmy Carter was treated with KEYTRUDA along with radiation therapy for advanced melanoma that had spread to his brain. The combination worked so well, causing his tumors to disappear; that he was able to stop treatment.
“Hematogenix Laboratory Services, LLC (Hematogenix)- Announces the Launch of two U.S. Food and Drug Administration (FDA) Approved PD-L1 Companion Diagnostic Tests to Help Guide Oncologists Using Immuno-Oncology Therapies
TINLEY PARK, Ill., April 25, 2016 /PRNewswire/ — Hematogenix, an industry leader in the field of integrated pathology services for drug development and clinical testing, announces the availability of the FDA approved PD-L1 companion diagnostic assays PD-L1 IHC 22C3 pharmDx for KEYTRUDA(R), Merck’s Anti-PD-1 therapy for metastatic non-small cell lung cancer, and PD-L1 IHC 28-8 pharmDx, a complementary diagnostic assay to support Bristol-Myers Squibb’s OPDIVO(R) anti-PD-1 therapy for non-squamous non-small cell lung cancer. Both kits are available through Dako, an Agilent Technologies company. Learn more about Hematogenix’s comprehensive biomarker development and testing services at www.hematogenix.com.”
Hematogenix Laboratory Service is a private company.
Merck and Co., Inc. MRK has an YTD return of 7.31%. It is currently showing a hybrid oversold at 2.59 with the threshold at 2.43. Debt/Equity 0.17, PE 36.04, Price/Cash 4.84, Price/Sales 3.99, Free Cash Flow (ttm) 11.14b, Net Cash per Share -4.73, Net Cash per Share / Price -0.08, Net income 14.43b, Operating Cash Flow (ttm) 12.42b, Revenue (ttm) 39.50, Total Cash 13.43b,Total Debt 26.54b. Return since 11/06/08 171.27. Dividend Yield 3.24.
Agilent Technologies A has an YTD return of -0.19, Debt/Equity 0.13, PE 30.19, Price/Cash 5.89, Price/Sales 3.39, Free Cash Flow (ttm) 519.00m, Net income 819.00m, Operating Cash Flow (ttm) 617.00m, Revenue (ttm) 4.04b, Total Cash 1.93b, Total Debt 1.73b. Return since 11/06/08 181.83. Dividend Yield 1.1.
“Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck & Co., Inc., maker of the anti-PD-1 therapy KEYTRUDA(R) (pembrolizumab). KEYTRUDA is approved by the FDA to treat patients with metastatic NSCLC whose tumors express PD-L1 as determined by the companion diagnostic assay and who have disease progression on or after platinum-containing chemotherapy.”
Bristol-Myers Squibb Company BMY has a YTD return of 3.2%, Debt/Equity 0.06, PE 75.95, Price/Cash 2.56, Price/Sales 7.13, Free Cash Flow (ttm) 1.30b, Net Cash per Share -1.46, Net Cash per Share/Price -0.02, Net Income 4.98b, Operating cash flow (ttm) 1.83b, Revenue (ttm) 16.56b, Total Cash 4.27b, Total Debt 6.70b, Return since 11/06/08 171.27. Dividend Yield 2.15
“Bristol-Myers Squibb Company BMY, -0.07% said early Monday that the Food and Drug Administration would expedite the development and review of its head and neck cancer drug Opdivo on the strength of its phase 3 trial results. Opdivo, which received the special status for the potential indication of recurrent or metastatic squamous cell carcinoma of the head and neck after therapy, also previously got the designation for the purposes of Hodgkin lymphoma, previously treated advanced melanoma, previously treated non-squamous non-small cell lung cancer and advanced or metastatic renal cell carcinoma. According to Bristol-Myers Squibb, nearly all of head-and-neck cancers are classified as squamous cell carcinoma. The company’s stock was up 0.5% in pre-market trade.”
If you enjoy the content at iBankCoin, please follow us on Twitter
